Evidence mapPaperPMID 21098138Full record

ReviewClinical chemistry2011

Therapeutic approaches to target inflammation in type 2 diabetes.

Allison B Goldfine, Vivian Fonseca, Steven E Shoelson

Open access · bronzeAbstract readReview
In one paragraph

Review in Clinical chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Depletion of myeloid-derived Zbtb46Journal of advanced research · 2026
    Article
  8. Frontiers in pharmacology · 2025
    Article
  9. Effects of ibuprofen in the ZDF rat model of type 2 diabetes.Journal of food and drug analysis · 2024
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Allison B GoldfineJoslin Diabetes Center, Harvard Medical School, Boston, MA 02115, USA. allison.goldfine@joslin.harvard.edu
Vivian Fonseca
Steven E Shoelson
Harvard University · USJoslin Diabetes Center · USTulane University · US

Funding

Zoledronic Acid in Treatment of Osteoporosis in PostmenoM01RR002635 · BRIGHAM AND WOMEN'S HOSPITAL · 1985 to 2005
$35.1M
ZINC STATUS AND T CELL DISORDER IN MILD HUMAN ZINC DEFICIENCYM01RR001032 · BETH ISRAEL DEACONESS MEDICAL CENTER · 1985 to 2005
$23.6M
PILOT STUDY--SECRETORY TARGETING IN PANCREATIC B CELLSP30DK036836 · JOSLIN DIABETES CENTER · 1986 to 2025
$12.1M
RECEPTOR/SUBSTRATE COMPLEXES IN TRANSMEMBRANE SIGNALINGR01DK051729 · JOSLIN DIABETES CENTER · 1996 to 2004
$2.1M
POTENTIAL CAUSE &MOLECULAR TARGET OF INSULIN RESISTANCR01DK045943 · JOSLIN DIABETES CENTER · 1996 to 2005
$1.6M
MEDIATORS AND MODIFIERS OF NF-kB IN INSULIN RESISTANCER37DK051729 · JOSLIN DIABETES CENTER · 2005 to 2005
$442k
NCRR NIH HHS M01 RR001032NCRR NIH HHS M01 RR002635NHLBI NIH HHS P50 HL083813NHLBI NIH HHS P50HL083813NHLBI NIH HHS R01 HL091750NHLBI NIH HHS R01HL091750NIDDK NIH HHS P30 DK036836NIDDK NIH HHS P30DK036836NIDDK NIH HHS R01 DK045943NIDDK NIH HHS R01 DK051729NIDDK NIH HHS R01 DK073547NIDDK NIH HHS R37 DK051729NIDDK NIH HHS RC4 DK090792NIDDK NIH HHS U01 DK074556NIDDK NIH HHS U01DK074556
6 · The paper itself

Abstract

backgroundChronic inflammation may participate in the pathogenesis of insulin resistance, type 2 diabetes, and cardiovascular disease and may be a common denominator that links obesity to these disease states. CONTENT: Epidemiologic studies have linked inflammatory biomarkers to incident diabetes and cardiovascular disease risk. Cellular and animal studies have provided support to the idea that inflammation mediates these disease processes, providing impetus to pharmacologically target these pathways for disease treatment and prevention. We review clinical strategies to target inflammation, with a focus on the antiinflammatory and antihyperglycemic effects of salicylates. SUMMARY: The evolving concept of diet-induced obesity driving insulin resistance, type 2 diabetes, and cardiovascular disease through immunologic processes provides new opportunities for the use of antiinflammatory strategies to correct the metabolic consequences of excess adiposity.

Indexed as

Adipose TissueAnimalsAnti-Inflammatory Agents, Non-SteroidalCardiovascular DiseasesDiabetes Mellitus, Type 2HumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsInflammationInsulin ResistanceObesitySalicylatesAnti-Inflammatory Agents, Non-SteroidalHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsSalicylates

Identifiers

PMID21098138
PMCPMC3227024
OpenAlexW2011373763

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.